ALGS Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. (ALGS) is expected to report earnings on February 5, 2027, before the market open. The consensus earnings estimate is a loss of $2.03 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -62.6% since its last earnings release on November 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases and viral infections.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.